Literature DB >> 23826022

Pulmonary emboli following oral contraceptive misuse and long air travel.

Toba Kazemi1, Seyed Alireza Javadinia.   

Abstract

Entities:  

Year:  2012        PMID: 23826022      PMCID: PMC3697220     

Source DB:  PubMed          Journal:  J Res Med Sci        ISSN: 1735-1995            Impact factor:   1.852


× No keyword cloud information.
Sir, We read the article “oral contraceptive misuse as a risk factor for cerebral venous and sinus thrombosis” by “Saadat-niya et al,” which has been published in the recent issue of your journal.[1] It was a very interesting article. As it was emphasized in the article, taking oral contraceptives has been increasing to a great extent in Iran in recent years and more than 2/3 of women at fertility age do so.[12] Although the main goal of taking such pills is to postpone conception and control population growth, these pills are also being used to postpone menstruation during the blessed Ramadan month and Mecca (Haj) pilgrimage.[1] After the Advantageous Mecca pilgrimage (Haj-e-tamatto) of last year (2011), a 38-year-old woman with deep vein thrombosis of the left leg was hospitalized in the cardiology ward of Valli-e-asr hospital in Birjand. Misuse of oral contraceptives (two times the normal dose) for two months and long-time flight journies were considered to be the underlying causes. On the second day, because of not taking complete bedrest, acute pulmonary emboli (PE) was occured. PE was diagnosed timely and confirmed through transthorasic echocardiography and CT angiography. The patient was administered thrombolytic drugs and now, while she is feeling well, is using warfarin. Misuse and taking without a physician’s prescription of oral contraceptives, usually with over-normal dose, occured and this intensified the side-effects of these drugs.[13] One of the most important side effects of such pills concerns the cardiovascular system. The incidence of venous thromboembolism (VTE) in healthy women is 4–5/10000 per year, but the risk reaches 9–10/10000 women per year among those taking oral contraceptives; and if other risk factors like sedentary lifestyle are added the chance of thromboembolism further increases.[4] Various studies have been conducted to explore the relationship between long flight journey and thromboembolism, in the majority of which such a relationship has been observed. This risk further increases if other predisposing factors such as sitting position of the passenger, inactivity, relative hypoxia, dehydration following taking diuretics like tea, and hot weather.[5] Therefore, these factors should be considered in any long lasting trip.[5]
  5 in total

1.  Hormonal contraception--what kind, when, and for whom?

Authors:  Inka Wiegratz; Christian J Thaler
Journal:  Dtsch Arztebl Int       Date:  2011-07-18       Impact factor: 5.594

2.  The association of contraceptive methods and depression.

Authors:  Soheila Ehsanpour; Arezo Aghaii; Gholam Reza Kheirabadi
Journal:  Iran J Nurs Midwifery Res       Date:  2012-03

3.  Dissatisfaction with contraceptive methods.

Authors:  Nahid Fathizadeh; Parisa Salemi; Soheila Ehsanpour
Journal:  Iran J Nurs Midwifery Res       Date:  2011

4.  Oral contraceptive misuse as a risk factor for cerebral venous and sinus thrombosis.

Authors:  Mohammad Saadatnia; Neda Naghavi; Farzad Fatehi; Mohammad Zare; Marzieh Tajmirriahi
Journal:  J Res Med Sci       Date:  2012-04       Impact factor: 1.852

Review 5.  The association between air travel and deep vein thrombosis: systematic review & meta-analysis.

Authors:  Yaser Adi; Sue Bayliss; Andrew Rouse; R S Taylor
Journal:  BMC Cardiovasc Disord       Date:  2004-05-19       Impact factor: 2.298

  5 in total
  1 in total

1.  V/Q scans and computerized tomography pulmonary angiography in pulmonary emboli in pregnancy: Superiority for fetal or mother.

Authors:  Nahid Azdaki; Mahmood Hosseinzadeh Maleki; Toba Kazemi; Seyyed Ali Moezi; Hamid Reza Mashraghi Moghaddam
Journal:  J Res Med Sci       Date:  2014-07       Impact factor: 1.852

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.